Earnings
EBIT and EBITDA
Earnings before interest and tax (EBIT) fell sharply, by €520.6 million, to €103.3 million in the first nine months of 2022 (Q1–Q3 2021: €623.9 million). EBIT included budgeted purchase price allocation effects amounting to an expense of €69.0 million in the first three quarters of the year (Q1–Q3 2021: expense of €63.1 million). In the reporting period, there were also non-recurring items amounting to a total expense of €38.3 million (Q1–Q3 2021: expense of €4.1 million) that essentially reflected impairment losses on assets of the Russian subsidiaries.
EBIT adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) decreased to €210.6 million (Q1–Q3 2021: €691.1 million). The adjusted EBIT margin fell sharply to 2.6 percent as a result (Q1–Q3 2021: 9.2 percent). In the third quarter, adjusted EBIT amounted to minus €101.1 million (Q3 2021: €228.9 million). This loss was primarily attributable to the rise in expected overall project costs in the SCS segment.
in € million |
Q3 |
Q3 |
Q1 – Q3 |
in % of revenue |
Q1 – Q3 |
in % of revenue |
---|---|---|---|---|---|---|
EBIT |
–131.2 |
209.1 |
103.3 |
1.3% |
623.9 |
8.3% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
16.2 |
9.5 |
44.7 |
0.5% |
28.4 |
0.4% |
+ Selling expenses and administrative expenses |
14.1 |
13.0 |
48.5 |
0.6% |
42.5 |
0.6% |
+ Research and development costs |
0.1 |
0.0 |
0.1 |
0.0% |
0.1 |
0.0% |
+ Other costs |
–0.2 |
–2.8 |
14.0 |
0.2% |
–3.9 |
–0.1% |
Adjusted EBIT |
–101.1 |
228.9 |
210.6 |
2.6% |
691.1 |
9.2% |
adjusted for non-recurring items |
6.2 |
–1.4 |
38.3 |
0.5% |
4.1 |
0.1% |
adjusted for PPA items |
24.0 |
21.2 |
69.0 |
0.8% |
63.1 |
0.8% |
Earnings before interest, tax, depreciation, and amortization (EBITDA) stood at just €867.9 million in the reporting period (Q1–Q3 2021: €1,317.6 million). Adjusted EBITDA was also down markedly at €893.8 million (Q1–Q3 2021: €1,321.4 million), giving an adjusted EBITDA margin of 10.8 percent (Q1–Q3 2021: 17.5 percent).
in € million |
Q3 |
Q3 |
Q1 – Q3 |
in % of revenue |
Q1 – Q3 |
in % of revenue |
---|---|---|---|---|---|---|
EBITDA |
128.4 |
443.7 |
867.9 |
10.5% |
1,317.6 |
17.5% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
5.4 |
–0.0 |
13.8 |
0.2% |
0.0 |
0.0% |
+ Selling expenses and administrative expenses |
0.9 |
1.4 |
10.4 |
0.1% |
8.0 |
0.1% |
+ Research and development costs |
0.1 |
0.0 |
0.1 |
0.0% |
0.0 |
0.0% |
+ Other costs |
–0.2 |
–3.2 |
1.6 |
0.0% |
–4.2 |
–0.1% |
Adjusted EBITDA |
134.6 |
441.9 |
893.8 |
10.8% |
1,321.4 |
17.5% |
adjusted for non-recurring items |
6.2 |
–1.9 |
25.9 |
0.3% |
3.8 |
0.0% |
adjusted for PPA items |
0.0 |
0.0 |
0.0 |
0.0% |
0.0 |
0.0% |